What is the guideline‑recommended pharmacologic treatment for heart failure with reduced ejection fraction?

Guideline-Directed Medical Therapy for Heart Failure with Reduced Ejection Fraction

All patients with HFrEF should be treated with four foundational drug classes: an ACE inhibitor (or ARNI), a beta-blocker, a mineralocorticoid receptor antagonist (MRA), and an SGLT2 inhibitor, initiated rapidly within 2-4 weeks of diagnosis to reduce mortality and hospitalization. 1

Core Pharmacologic Treatment Algorithm

First-Line Quadruple Therapy (Class I Recommendations)

The 2022 AHA/ACC/HFSA guidelines establish SGLT2 inhibitors as the fourth pillar of GDMT, fundamentally changing the treatment paradigm 1. The evidence-based approach consists of:

1. ACE Inhibitor or ARNI (Class I, Level A)

• Start with an ACE inhibitor in all symptomatic HFrEF patients 2
• Replace with sacubitril/valsartan (ARNI) in patients who remain symptomatic despite optimal ACE inhibitor, beta-blocker, and MRA therapy 2
• ARNI reduces cardiovascular death and HF hospitalization by 20% compared to enalapril 3
• If ACE inhibitor intolerant, use ARB (Class I, Level A) 2

2. Beta-Blocker (Class I, Level A)

• Initiate in addition to ACE inhibitor for all stable, symptomatic HFrEF patients 2
• Evidence-based agents: carvedilol, metoprolol succinate, bisoprolol
• Reduces risk of HF hospitalization and death 2

3. Mineralocorticoid Receptor Antagonist (Class I, Level A)

• Add for patients remaining symptomatic despite ACE inhibitor and beta-blocker 2
• Spironolactone recommended in NYHA class III-IV to improve survival and morbidity 4
• Monitor potassium and renal function closely

4. SGLT2 Inhibitor (Class I, Level A)

• Now a foundational therapy regardless of diabetes status 1
• Initiate early in treatment course
• Proven mortality and morbidity benefit in HFrEF

Rapid Sequencing Strategy

The conventional 6-month titration approach is outdated. Modern evidence supports rapid initiation within 2-4 weeks 5:

Week 1-2:

• Simultaneously start beta-blocker + SGLT2 inhibitor
• These have the best safety profiles and can enhance tolerability of subsequent agents

Week 2-3:

• Initiate sacubitril/valsartan (or ACE inhibitor if ARNI not appropriate)
• Wait 36 hours after last ACE inhibitor dose before starting ARNI to avoid angioedema

Week 3-4:

• Add MRA
• Check potassium and creatinine 5-7 days after initiation 4

Critical principle: Achieving low doses of all four drug classes takes precedence over up-titrating to target doses of fewer agents 5. Low starting doses provide substantial therapeutic benefit, and the efficacy of each class is independent of the others.

Additional Therapies for Selected Patients

Diuretics (Class I, Level B)

• Required for all patients with signs/symptoms of congestion 2
• Loop diuretics preferred; add thiazides for synergy if inadequate response 4
• Not for mortality reduction—purely symptomatic relief

Digoxin (Class I, Level B)

• For atrial fibrillation with any degree of symptomatic HF to control ventricular rate 4
• In sinus rhythm: improves clinical status in persistent symptoms despite ACE inhibitor and diuretic 4
• Usual dose: 0.25-0.375 mg daily (0.125-0.25 mg in elderly) 4

Hydralazine/Nitrate Combination

• Particularly for Black patients with HFrEF 6
• Consider when other agents contraindicated or not tolerated

Critical Monitoring Parameters

After each dose increment and at 3 months, then every 6 months, check: 4

• Blood pressure
• Renal function (creatinine, GFR)
• Electrolytes (especially potassium)

For MRA specifically: Check potassium and creatinine 5-7 days after initiation and after each dose change until stable 4

Medications That Cause Harm (Class III)

Absolutely avoid:

• Non-dihydropyridine calcium channel blockers (diltiazem, verapamil): increase HF worsening and hospitalization (Class III, Level C) 2
• NSAIDs: worsen HF symptoms, should be withdrawn whenever possible 7
• Thiazolidinediones: increase HF symptoms and hospitalizations 7
• Class IC antiarrhythmics and dronedarone: increase mortality risk 7
• DPP-4 inhibitors (saxagliptin, alogliptin): increase HF hospitalization in diabetics 7

Triple renin-angiotensin system blockade: Do not combine ACE inhibitor + ARB + MRA due to increased risk of renal dysfunction and hyperkalemia (Class III, Level C) 2

Common Pitfalls and Solutions

Pitfall #1: Accepting suboptimal doses without attempting titration

• Real-world data shows only 1.3% of patients achieve target doses for all four classes 8
• However, physicians often accept suboptimal doses without medical justification 8
• Continue titration attempts beyond the first 60 days

Pitfall #2: Permanent discontinuation after side effects

• Discontinuation rates range 9-13% across drug classes 8
• Rechallenge is successful in over 83% of patients 8
• Always attempt rechallenge after side effect resolution

Pitfall #3: Delaying ARNI initiation

• Can be started as first-line therapy or after ACE inhibitor titration 1, 6
• Don't wait for "optimal" ACE inhibitor dosing—symptomatic patients benefit from earlier switch

Pitfall #4: Withholding therapy in older patients or those with comorbidities

• Real-world data shows underutilization in elderly, those with COPD, prior stroke, or dementia 9
• Age and comorbidities are not contraindications unless specific drug-related concerns exist

Special Consideration: Improved LVEF

Patients with previously documented HFrEF who now have LVEF >40% should continue all HFrEF therapies 1. This "improved LVEF" phenotype still benefits from continued GDMT.